| Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, ... The Lancet 397 (10275), 671-681, 2021 | 2206 | 2021 |
| Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia DY Logunov, IV Dolzhikova, OV Zubkova, AI Tukhvatulin, ... The Lancet 396 (10255), 887-897, 2020 | 1328 | 2020 |
| Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia IV Dolzhikova, OV Zubkova, AI Tukhvatulin, AS Dzharullaeva, ... Human vaccines & immunotherapeutics 13 (3), 613-620, 2017 | 150 | 2017 |
| Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow endemic SARS … VA Gushchin, IV Dolzhikova, AM Shchetinin, AS Odintsova, AE Siniavin, ... Vaccines 9 (7), 779, 2021 | 138 | 2021 |
| SERS-based aptasensor for rapid quantitative detection of SARS-CoV-2 E Zavyalova, O Ambartsumyan, G Zhdanov, D Gribanyov, V Gushchin, ... Nanomaterials 11 (6), 1394, 2021 | 76 | 2021 |
| An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in … AI Tukhvatulin, IV Dolzhikova, DV Shcheblyakov, OV Zubkova, ... The Lancet Regional Health–Europe 11, 2021 | 71 | 2021 |
| Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses AI Tukhvatulin, AS Dzharullaeva, NM Tukhvatulina, DV Shcheblyakov, ... PLoS One 11 (5), e0155650, 2016 | 55 | 2016 |
| Virus-vectored Ebola vaccines IV Dolzhikova, EA Tokarskaya, AS Dzharullaeva, AI Tukhvatulin, ... Acta Naturae (англоязычная версия) 9 (3 (33)), 4-11, 2017 | 36 | 2017 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific T cells and antibodies in coronavirus disease 2019 (COVID-19) protection: a prospective study IA Molodtsov, E Kegeles, AN Mitin, O Mityaeva, OE Musatova, AE Panova, ... Clinical Infectious Diseases 75 (1), e1-e9, 2022 | 34* | 2022 |
| Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern IA Favorskaya, DV Shcheblyakov, IB Esmagambetov, IV Dolzhikova, ... Frontiers in immunology 13, 822159, 2022 | 34 | 2022 |
| Retention of neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V-vaccinated individuals D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, ... Vaccines 10 (5), 817, 2022 | 33 | 2022 |
| Safety and efficacy of the Russian COVID-19 vaccine: more information needed–Authors’ reply DY Logunov, IV Dolzhikova, AI Tukhvatullin, DV Shcheblyakov The Lancet 396 (10256), e54-e55, 2020 | 30 | 2020 |
| Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B. 1.1. 529 (Omicron) SARS-CoV-2 variant IV Dolzhikova, AA Iliukhina, AV Kovyrshina, AV Kuzina, VA Gushchin, ... medRxiv, 2021.12. 17.21267976, 2021 | 26 | 2021 |
| Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma AI Kostin, MN Lundgren, AY Bulanov, EA Ladygina, KS Chirkova, ... Vox sanguinis 116 (6), 665-672, 2021 | 22 | 2021 |
| Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis DA Burmistrova, SV Tillib, DV Shcheblyakov, IV Dolzhikova, ... PLoS One 11 (3), e0150958, 2016 | 22 | 2016 |
| Boosting of the SARS-coV-2–specific immune response after vaccination with single-dose sputnik light vaccine AA Komissarov, IV Dolzhikova, GA Efimov, DY Logunov, O Mityaeva, ... The Journal of Immunology 208 (5), 1139-1145, 2022 | 20 | 2022 |
| Fast and accurate surrogate virus neutralization test based on antibody-mediated blocking of the interaction of ACE2 and SARS-CoV-2 spike protein RBD DE Kolesov, MV Sinegubova, LK Dayanova, IV Dolzhikova, II Vorobiev, ... Diagnostics 12 (2), 393, 2022 | 20 | 2022 |
| Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial–Authors' reply DY Logunov, IV Dolzhikova, DV Shcheblyakov Lancet (London, England) 397 (10288), 1883, 2021 | 20 | 2021 |
| Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates AI Tukhvatulin, IV Gordeychuk, IV Dolzhikova, AS Dzharullaeva, ... Emerging Microbes & Infections 11 (1), 2229-2247, 2022 | 19 | 2022 |
| In vitro efficacy of antivirals and monoclonal antibodies against SARS-CoV-2 Omicron lineages XBB. 1.9. 1, XBB. 1.9. 3, XBB. 1.5, XBB. 1.16, XBB. 2.4, BQ. 1.1. 45, CH. 1.1, and … AA Pochtovyi, DD Kustova, AE Siniavin, IV Dolzhikova, EV Shidlovskaya, ... Vaccines 11 (10), 1533, 2023 | 16 | 2023 |
Amir TukhvatulinN.F.Gamaleya National Research Center for Epidemiology and MicrobiologyVahvistettu sähköpostiosoite verkkotunnuksessa gamaleya.org
